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The diversity of autoantibodies produced in systemic lupus erythematosus (SLE) 1 
(1)  differentiates this disease from other autoimmune disorders in which the auto- 
antibodies  react  with  a  narrow  range  of antigenic  determinants.  In  autoimmune 
thyrotoxicosis (2), myasthenia gravis (3), and autoimmune hemolytic anemia (4), as 
examples, the diversity of autoantibody reactions is limited by comparison with the 
serological findings in SLE. A typical lupus serum can react with nucleic acids (native 
or denatured DNA;  RNA)  and nucleoproteins (Sm and RNP  antigens; ribosomes; 
nucleohistones), cell surface antigens, cardiolipin, and certain coagulant activities of 
the blood, but usually not with any organ- or receptor-specific autoantigens (reviewed 
in [1]). Therefore, there is restricted heterogeneity within the serological polymorphism 
of SLE. The extent of autoantibody diversity in SLE is of fundamental importance 
because it pertains to the widely held view that this disease is a result of a generalized 
disturbance of the immune system (5, 6). 
We have undertaken an analysis of the diversity of lupus autoantibodies by means 
of hybridoma technology (7, 8). The advantage of this method over analysis of serum 
antibodies is that individual molecular species of autoantibody can be examined so 
that true diversity can be distinguished from cross-reactivity. The hybridomas under 
study were prepared by fusion of spleen cells from unimmunized MRL/1 mice with 
mouse myeloma cells. MRL/1 mice were chosen because they spontaneously develop 
a severe form of SLE and because they produce high levels of anti-DNA antibodies 
(9).  Some of the hybridoma anti-DNA autoantibodies we prepared have an immu- 
nochemical preference for particular purine bases, whereas others react with a  wide 
range of polynucleotides (8). The latter kind of autoantibody might be reactive with 
the sugar-phosphate backbone of nucleic acids, a structural feature of all polynucle- 
otides  (8).  The  sugar-phosphate  backbone  of nucleic  acids  consists  of phosphate 
groups, in phosphodiester linkage, separated by three carbon atoms of adjacent sugar 
molecules. The  phospholipid cardiolipin also contains phosphodiester-linked phos- 
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phate groups that are separated by three carbon atoms. In these experiments we show 
that monoclonal anti-DNA autoantibodies that bind to a  variety of polynucleotides 
can react with phospholipids, including cardiolipin, and also mimic the in vitro action 
of a lupus anticoagulant. The serological diversity of certain lupus autoantibodies can 
therefore  be  explained  by  their  reactivity  with  appropriately  spaced  phosphate 
residues that are present in a  variety of biological molecules. 
Materials  and  Methods 
Hybridoma Autoantibodies and Anti-Idiotypes.  The fusion of spleen cells of MRL/1  mice with 
either Sp2/O-Ag-14 or MPC-11  plamacytomas, selection of cell lines producing anti-DNA 
antibodies, cloning and subcloning of these lines, purification of  their immunoglobulin products, 
measurement of the nucleic acid-binding specificity, and production and characterization of 
anti-idiotype antibodies were all described in detail previously (7,  8).  Hybridoma H43  is a 
fusion with MPC-11, whereas hybridomas H 102, H 104, and H 130 are fusions with Sp2/O-Ag- 
14. 
Preparation of Phospholipid Micelles.  Purified  phospholipids obtained  from  Supelco,  Inc., 
Bellefonte, Pa. were supplied in either chloroform or chloroform:methanol (2:1). 12-rag samples 
were transferred to  15-ml Pyrex conical test tubes and the organic solvents were evaporated 
under a nitrogen stream. Micelles were created by the slow addition of 6 ml of standard saline 
citrate (0.15 M  NaC1, 0.015 M  citrate, pH 7) to the tubes, with frequent vortex mixing, and 
incubation of the mixtures at 37°C for 15 min. 
Competition for Hybridoma Antibody Binding to Denatured DNA  (dDNA).  Samples (100  pg) of 
hybridoma immunoglobulin diluted in phosphate-EDTA buffer (60 mM potassium phosphate, 
30  mM  EDTA,  pH  8)  were  incubated  with  varying  concentrations  of either  dDNA  or 
phospholipid micelles in 100 pl of the same buffer in 1.5-ml microfuge tubes for 30 rain at room 
temperature.  [3H]Thymidine-labeled dDNA  (75  ng)  in  50  pl  of phosphate-EDTA  buffer 
prepared as described elsewhere (8) was added and the incubation continued for another 1 h. 
Then 50 pl of the gammaglobulin fraction of goat anti-mouse Ig serum (8) was added, and the 
mixture was  kept  at  room  temperature  for  1 h.  The  resulting precipitate was centrifuged, 
washed twice with  1 ml of phosphate-EDTA buffer, dissolved in 0.2 ml of 0.1  N  NaOH, and 
counted in 3 ml of Beckman Ready-Solv HP (Beckman Instruments, Inc., Fullerton, Calif.) in 
microvials. 
Competition for Hybridoma Antibody Binding  to dDNA  on a  Solid Phase.  Samples  (100  #1)  of 
hybridoma antibody, diluted in 0.1 M  KPO4, pH 7, buffer with 0.5% fetal calf serum added to 
prevent nonspecific binding, were incubated with various amounts of either dDNA or phos- 
pholipid micelles in I00/~1 of the same buffer for 1 h at 37°C. Aliquots (75/xl)  of the mixtures 
were then  transferred in  duplicate to polystyrene tubes coated with  5/tg of dDNA  (7)  and 
incubated for 30 min at 37°C. The solution was aspirated and  the tubes washed twice with 
buffer, x25I-labeled affinity-purified goat anti-mouse Ig was added and the tubes were incubated 
for 45 min at room temperature. The solution was aspirated and the tubes were washed three 
times with buffer and assayed for 12sI. 
Inhibition of Idiotype-Anti-Idiotype Reactions.  12SI-labeled hybridoma antibody was incubated 
with dDNA or phospholipids in glass tubes for  1 h  at 37°C. This mixture (100 pl) was then 
transferred to washed anti-idiotype-coated tubes and  incubated for  1 h  at  37°C.  The tubes 
were washed three times with phosphate buffer and counted for ~zsI. 
Inhibition  of Antinuclear Antibody Reactions.  Cardiolipin  or  phosphatidyl  ethanolamine  in 
concentrations indicated in Results were mixed with an equal volume of hybridoma culture 
fluid for  1 h  at  37°C.  An aliquot of the mixture was then  tested for antinuclear antibody 
reactivity by a previously described method (7). 
Anticoagulant Properties of Monoclonal Antibodies.  The anticoagulant properties of the mono- 
clonal  antibody  preparations  added  to  plasma  were  assessed  using  the  activated  partial 
thromboplastin time (10).  Normal human plasma was obtained after centrifugation of whole 
blood, anticoagulated with one part 3.8% sodium citrate to nine parts whole blood. Before use, 
pooled plasma was recentrifuged at  35,000 g.  Normal  pooled plasma  (0.2  ml), monoclonal 
antibody solution in 0. I M Tris-HCl, pH 7.6 (0.2 ml), and phospholipid (Thrombofax Reagent; LAFER ET AL.  899 
Ortho Pharmaceutical Corp., Raritan, N. J.) diluted 1:32 or 1:64 in 0.1 M Tris-HCl, pH 7.6; 
0.4 ml were incubated at 37°C for 2 h. Kaolin (2 mg/ml in 0.1 M Tris-HCl, pH 7.6; 0.1 ml) 
was added to 0.2 ml of the above solution and incubated for 15 min at 37  °.  Clotting was 
initiated with the addition of 25 mM CaCl2 (0.1 ml) and the time to clot formation recorded. 
As a control, tests were performed in which the monoclonal antibody solution was replaced by 
the Tris buffer. All assays were performed in duplicate. 
Isoelectric Focusing.  Isoelectric focusing in agarose  (Isogel; Marine Colloids, Inc., Rockland, 
Maine) was performed according to the method of Saravis and Zamcheck (11), in which 0.5% 
agarose gels that containing 2.5% Ampholytes (Ampholytes or Pharmalytes; LKB Instruments, 
Inc., Rockville, Md.) of the desired pH range were poured on GelBond (Marine Colloids, Inc.) 
-covered preheated glass plates and stored 1-24 h at 4°C in a humid chamber before use. Horse 
ferritin (isoelectric point [pI] 4.1-4.7)  and human hemoglobin (pI 6.7), kindly supplied by J. 
Drysdale, served  as  marker proteins.  Immediately after focusing,  gels were  sliced  for pH 
measurements.  In addition, 0.5-cm slices of gels were eluted into 0.5 ml of 0.1 M KPO4-0.5% 
fetal calf serum buffer, and aliquots of these eluates were then tested in the DNA-binding assay 
and were also analyzed for Ig content in a solid-phase  radioimmunoassay (RIA)  using goat 
anti-mouse-Ig-coated tubes (8). 
Results 
Reactivity of Anti-DNA Autoantibodies with Phospholipids.  Hybridoma autoantibodies 
H130, H104, and H102 react with a  variety of polynucleotides, whereas H43 has a 
marked preference for a  guanine -or hypoxanthine-containing determinant  (8).  The 
results with the first three autoantibodies suggest that they bind to polynucleotides by 
reaction  with  the  sugar-phosphate  backbone,  a  structure  that  contains  repeating 
phosphodiester linkages. The presence of such linkages in phospholipids led us to test 
the hypothesis that monoclonal autoantibodies  that bind to DNA can also bind to 
phospholipids.  Fig.  1 shows  the  results  of RIA  in  which  either dDNA  or various 
phospholipids were used as competitors of the binding of the autoantibodies H130, 
H104,  H102,  and  H43 to dDNA.  In  the ease of H130  (Fig.  1A),  both eardiolipin 
(diphosphatidyl glycerol) and phosphatidic acid competed as well as or better than 
dDNA;  50% inhibition was achieved with ~0.12 nmol eardiolipin, 0.16 nmol phos- 
phatidic acid, and 0.20 nmol dDNA  (molar equivalents for both phospholipids and 
dDNA are expressed in terms of phosphorous content). Phosphatidyl glycerol was a 
weaker  inhibitor than  either cardiolipin  or phosphatidic  acid  and  50%  inhibition 
required  15  nmol.  Phosphatidyl  serine,  phosphatidyl  choline,  and  phosphatidyl 
ethanolamine failed to inhibit the reaction in amounts up to 100 nmol. 
Similar  results  were obtained  with  H104  (Fig.  1B).  The  amounts  (in  nmol)  of 
cardiolipin, phosphatidic acid,  dDNA,  and  phosphatidyl glycerol that  caused  50% 
inhibition were: 0.20, 0.45, 0.40, and 9.0, respectively. In the case of H102 (Fig.  1C), 
dDNA was ~80 times more effective as a competitor than cardiolipin. Nevertheless, 
cardiolipin,  phosphatidie  acid,  and  phosphatidyl glycerol inhibited  the binding of 
this autoantibody to dDNA, but relatively high amounts  (16,  220, and ~250 nmol, 
respectively) were required for 50% inhibition. As with H 130 and H 104, phosphatidyl 
serine, phosphatidyl choline, and phosphatidyl ethanolamine failed to compete with 
H102  for  dDNA.  By  contrast  with  the  preceding  results,  H43,  the  base-specific 
autoantibody, was not inhibited by any of the phospholipids tested (Fig.  1 D). 
Inhibition of Idiotype-Anti-Idiotype  Reactions by Phospholipids.  Anti-idiotypic antibodies 
against  H102 and  H43, prepared in rabbits, have been shown to be site-specific in 
that  their ability to bind  to corresponding hybridoma autoantibody is completely 
inhibited by antigen (8). With H 102, the order of  inhibition by various polynucleotides iooj- 
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FIC.  1.  Competitive RIA with hybridoma antibodies that bind to dDNA. H130, H104, and H43 
were bound to dDNA on a  solid phase,  l~I-labeled,  affinity-purified goat anti-mouse Ig (40,000 
cpm) was added to detect bound hybridoma. The counts bound in the absence of inhibitor were: 
HI30,  667 cpm;  HI04,  622 cpm;  H43,  2,304 cpm;  normal Ig (MPC-I 1), 0  cpm. The amount of 
hybridoma antibody used was chosen so that the counts per minute bound increased linearly with 
increasing amount of the antibody. Purified MPC- 11 Ig was used at identical protein concentrations. 
H102 was bound to [~H]dDNA in solution phase. In the absence of inhibitor, HI02 bound 28.2% of 
the [3H]dDNA and normal Ig bound 2.0%.  Values represent the mean percent inhibition of dDNA 
binding for duplicate samples in the presence of indicated competitors. 
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is  the  same  as  the  order  of the  binding  preference  of this  autoantibody  for  the 
polynueleotides (8). Fig. 2 A shows the results when phospholipids were used to inhibit 
the reaction between H 102 and its anti-idiotypic antibody (anti-H102). Both cardio- 
lipin and phosphatidic acid effectively inhibited the reaction. Cardiolipin was  160 
times, and phosphatidic acid -15 times, more effective than dDNA as competitors in 
the H 102-anti-H 102 assay. It is also noteworthy that weak, but consistently reproduc- 
ible inhibition of the binding of H102  to its anti-idiotypic antibody was obtained 
with  phosphatidyl  ethanolamine,  phosphatidyl  glycerol, and  phosphatidyl serine. 
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munoassays, various concentrations of phospholipids or dDNA were incubated with  I-hybridoma 
antibody (idiotype) and the mixture was transferred to anti-idiotype-coated tubes. Values represent 
means ofduplicate samples. (A) Hl02/anti-H102;  (B) H43/anti-H43. LAFER  ET  AL.  903 
Phosphatidyl  choline,  by  contrast,  failed  to  inhibit  the  reaction.  None  of the  six 
phospholipids were effective inhibitors of the reaction between anti-H43 with  H43, 
the autoantibody with a  preference for purine bases. A  weak reaction, which never 
exceeded 20% inhibition, was found with phosphatidyl ethanolamine (Fig. 2 B). 
Inhibition of Antinuclear Reactions by Cardiolipin.  Monoclonal autoantibody H 102 was 
found to produce a strongly positive fluorescent antinuclear antibody reaction when 
tested  on  a  substrate  of rat  liver sections  (Fig.  3).  The  ability  of cardiolipin  and 
phosphatidyl ethanolamine to inhibit this serological reaction was tested by incuba- 
tion of H102 with the phospholipids before the test. The results in Table I show that 
the binding of H 102 to nuclei was completely inhibited by 50 #g/ml of cardiolipin. 
Phosphatidyl  ethanolamine,  however,  failed  to  inhibit  the  reaction.  Nine  other 
hybridoma autoantibodies that produce positive antinuclear reactions were also tested 
in this manner. Cardiolipin failed to inhibit the reaction in each of these cases. 
Anticoagulant  Activity  of Anti-DNA  Autoantibody.  The  anticoagulant  properties  of 
monoclonal anti-DNA antibodies were evaluated using the activated partial throm- 
boplastin time assay. In this clotting assay, the kaolin-activated intrinsic pathway of 
blood coagulation is tested with a  phospholipid  (Thrombofax) which substitutes for 
the in  vivo role of platelets.  To increase the sensitivity of the assay,  relatively low 
concentrations of phospholipid were used. In experiment A  (Table II), phospholipid 
stock solutions were diluted 1:64. As shown in Table II, H43, H104, and HI30 had no 
effect on the clotting time. However, H 102 significantly prolonged the clotting time. 
Fro.  3.  Antinuclear antibody reaction of ill02. 
TABLE  I 
Effect of Cardiolipin on the Antinudear Antibody Reactivity of H t 02 Antibody 
Concentration of cardiolipin  (mg/ml) 
0  0.00016  0.003  0.006  0.0125  0.025  0.05  0.1 
Fluorescence reaction  4 +*  3 +  3+  2  +  1  +  2  +  0  0 
* 4+, 3  +, 2  ÷, and  1+ represent a  qualitative estimate of the intensity of fluorescent staining from the most 
intense positive reaction (4+) to least intense positive antinuclear antibody (1+).  0 is no reaction. 904  POLYSPECIFIC MONOCLONAL LUPUS AUTOANTIBODIES 
TASL~ II 
Anticoagulant Properties of Monoclonal Antibodies: Effect on the Partial 
Thromboplastin Time 
Antibody  Clotting time 
concentration  Experiment A  Experiment 
I~g/rnl  s 
Buffer  0  7!..0, 71.8  52.2, 52.0 
H43  17  72.4, 72.8  53.0, 52.9 
170  71.8, 72.0  52.2, 53.0 
H102  14  75.0, 75.2  55.2, 54.8 
140  78.8, 78.6  56.0, 56.8 
Buffer  0  47.8, 48.2 
H104  27  47.8, 47.6 
267  42.4, 42.0 
H 130  28  48.0, 48.0 
280  41.0, 41.2 
For experiments in column A, the stock Thrombofax solution was used in a 
dilution of 1:64 and for experiments in column B, in a dilution of 1:32. The 
clotting time, in seconds, was measured from the initiation of clotting with 
kaolin and calcium to clot formation. H102 prolonged the partial thrombo- 
plastin time; H43, H104, and H130 had no effect. 
At final concentrations of H102 in the incubation mixture of 14 #g/ml and  140 #g/ 
ml,  the clotting time was increased by ~4 s and  7 s,  respectively.  In experiment  B 
(Table II), when the phospholipid stock solutions were diluted  1:32, H43, H104 and 
H130 again had no effect on the clotting time.  H102 at concentrations of 14 #g/ml 
and 140 #g/ml again prolonged the clotting time by 3 s and 4.5 s. 125I-labeled F(ab')2 
fragments of H102  failed  to  bind  to platelets,  whether  they were  activated or not 
(data not shown). This result resembles that obtained with a human monoclonal IgM 
paraprotein  that  binds  to  phospholipids  and  prolongs the  partial  thromboplastin 
time, but does not bind to platelets (12). The finding that Thrombofax, a commercial 
phospholipid  reagent  used  in  the  partial  thromboplastin  time  assay,  inhibited  the 
reaction of H102 with dDNA supports the interpretation  that  H102 prolonged the 
partial thromboplastin time by binding to a  phospholipid required for activation of 
the intrinsic blood coagulation pathway. Undiluted and fivefold-diluted Thrombofax 
inhibited  the  H102-dDNA reaction  by 60  and  30%,  respectively;  neither  amount 
inhibited the H43-dDNA interaction. 
Isoelectric  Focusing  of Hybridoma  Autoantibodies.  After the isoelectric focusing proce- 
dure,  fractions eluted  from  the  sliced  gels  were  assayed  for both  immunoglobulin 
content and binding to dDNA. The latter was done in the presence of either buffer or 
buffer containing 0.2 mg/ml cardiolipin. H43 gave a sharp dDNA-binding peak at pI 
8.05  (Fig.  4 A). The pattern  of !g content of the gel fractions of this protein had a 
broader  peak  than  the  DNA-binding  peak.  This  result  probably  represents  the 
presence  of MPC-11-derived  hybrid  molecules  that  do  not  bind  to  dDNA.  H102 LAFER  ET  AL.  905 
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showed a single peak of Ig at pI 7.05 which corresponded exactly to the peak of dDNA 
binding activity (Fig. 4 B).  The  latter was completely inhibited in  the presence of 
cardiolipin. H130  gave single, concordant peaks of Ig content and dDNA binding, 
both with pI of 6.85  (Fig. 4C). The peak dDNA binding was inhibited by 40% at the 
tested concentration of cardiolipin. 
H104  has reproducibly shown two superimposable  Ig and dDNA-binding peaks 
(Fig. 4D). The first, and largest, peak covers a pI range from 5.2-6.2. This peak has 
been found to increase during storage and with repeated freezing and thawing of the 
antibody. The second peak has a sharp pI of 7.1. Cardiolipin inhibited dDNA binding 
of the first peak by 50%,  but enhanced (twofold) the dDNA binding of the second 
peak.  H104  is unusual because it seems to consist mainly of •  chains. Analyses of 
H104  by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis  (Fig.  5) 
demonstrated a strongly staining band with an ~30,000 mol wt, but little staining in 
the position expected of heavy (H) chains. H chains could not be detected in H 104 by 
immunodiffusion with antisera directed against all classes  of Ig, but I¢ chains were 
readily found. This hybridoma product has a strong tendency to aggregate, and most 
of the  dDNA-binding  activity is  removed  by  centrifugation  at  80,000-100,000  g. 
These  results are  consistent with  the  interpretation  that  the  first broad  peak that 906  POLYSPECIFIC MONOCLONAL LUPUS AUTOANTIBODIES 
FIa.  5.  SDS-polyacrylamide  gel electrophoresis.  Lane 1:MPC-11 Ig; lane 4: human IgM; lane 7: 
HI04 Ig; lane 9:H102 Ig. 
H 104 shows on isoelectric focusing represents aggregates that vary in size and charge, 
whereas the second peak consists of nonaggregated material. The increased dDNA- 
binding activity brought about by cardiolipin may be the result of the aggregation of 
single light chains into a  favorable binding configuration. 
Discussion 
Our results with  monoclonal autoantibodies  demonstrate that  certain anti-DNA 
antibodies are serologically polymorphic, with the capacity to react with a  diversity 
of molecules. A single molecular species of autoantibody (e.g., H102) has been shown 
to  produce  many  of the  usual  serological  findings  of SLE:  a  positive antinuclear 
antibody  test,  antibody  reactions  with  DNA  and  other  polynucleotides, antibody 
reactions with cardiolipin, and prolongation of the activated partial thromboplastin 
test  that  is characteristic of a  lupus anticoagulant  (13).  These diverse reactions are 
apparently  a  result  of the  ability  of the  autoantibody  to  bind  to  structures  that 
contain  phosphate  esters.  The  identification  of such  lupus  autoantibodies  as  anti- 
DNA may thus be a fortuitous result of the choice of DNA as a test antigen. As noted 
previously, some of the monoclonal autoantibodies obtained from MRL/1 mice react 
strongly  with  polynucleotides other  than  DNA  (8)  as  do  some  of the  anti-DNA 
antibodies in human SLE sera (14). Therefore, both diversity of antibody populations 
(8,  14)  and  cross-reactions  of  individual  antibodies  appear  to  contribute  to  the 
serological heterogeneity observed in SLE. 
The chemical structure of cardiolipin resembles that of a  DNA backbone (Fig. 6), 
with phosphodiester-linked phosphate groups separated by an equal spacing of  carbon 
atoms.  This similarity may explain why anti-cardiolipin  antibodies  that were pro- 
duced  by rabbits  after injection of micelles with  cardiolipin  determinants  of their 
surface cross-reacted with  micelles into which  DNA  was  incorporated  (15).  Stollar 
(16)  has suggested that the polynucleotide backbone may form the determinant for 
many lupus autoantibodies, and that this property could account for the false-positive 
serological test for syphilis, which depends on a reaction with cardiolipin. 
The reactions of H 130, H 104, and H 102 with various phospholipids (Fig. 1) suggest 
that  regularly spaced phosphate  groups constitute the epitope for these antibodies. 
Presumably,  cardiolipin  and  dDNA  react  the  best  because  they contain  two  such 
groups separated by three carbon atoms.  Phosphatidic acid may react equally well 
because it presents a series of repeating phosphate determinants on a micellar surface. LAFER ET AL,  907 
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Phosphatidyl  glycerol  also  contains  a  large  part  of  the  determinant  present  in 
cardiolipin and dDNA.  By contrast, when phosphatidyl choline, phosphatidyl etha- 
nolamine, and phosphatidyl serine are presented on a micelle, the positively charged 
groups of these molecules also exposed to the aqueous solvent may interfere with the 
binding of the phosphate groups with the antibody. 
The results obtained with inhibition of the idiotype-anti-idiotype reaction (Fig. 2) 
support the interpretation that certain phospholipids can occupy the antigen-binding 
site of H 102 because anti-H 102 has been shown to be directed against a determinant (s) 
in the hypervariable region of H 102 (8). 
The multitude of serological reactions found in SLE has been an important element 
in  the  development  of theories  about  this  autoimmune  disease  (5,  6).  Our  results 
suggest that some of the diversity of autoantibody reactions in this disease may be a 
result, in part, of the presence of a relatively simple antigenic structure in a variety of 
biological  molecules.  We  are  currently  analyzing  a  large  number  of  hybridoma 
products to determine  the frequency of polyspecific  lupus autoantibodies. The pres- 
ence  of readily detectable  cardiolipin-binding antibodies  in serum  of MRL/1  mice 
(J. Rauch, unpublished observation) suggests that such antibodies may constitute an 
important fraction of the autoantibody population in these animals. 908  POLYSPECIFIC  MONOCLONAL LUPUS AUTOANTIBODIES 
Summary 
Hybridomas that  produce  anti-DNA  autoantibodies  were  prepared  from spleen 
cells  of unimmunized  MRL/1  mice,  a  strain  that  spontaneously  develops  severe 
systemic lupus erythematosus (SLE). Reactivities of these monoclonal antibodies with 
a wide range of polynucleotides prompted tests of their reactions with phospholipids 
which,  like polynucleoddes,  contain  diester-linked  phosphate  groups in  their back- 
bones. In competitive radioimmunoassays, cardiolipin, phosphatidic acid, and phos- 
phatidyl  glycerol blocked the binding of these  hybridoma antibodies  to denatured 
DNA. These phospholipids also specifically inhibited the reaction between a hybrid- 
oma antibody and a site-specific anti-idiotypic antibody. The antinuclear reaction of 
one of these antibodies was specifically inhibited by cardiolipin. This same antibody 
prolonged the activated partial thromboplastin time in a  manner characteristic of a 
lupus anticoagulant, presumably by binding to phospholipid in the test system. The 
polyspecific reactivity of a  single  molecular species of lupus  autoantibody suggests 
that  some of the  diverse  serological  abnormalities  of SLE  may be  a  result  of the 
binding  of certain  autoantibodies  to  a  phosphodiester-containing  epitope  that  is 
present in diverse biological molecules. 
Received  for publication 22 October 1980 and in revised  form  I0 December 1980. 
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